1 / 35

Meeting Public health challenges for controlling HCV infection

Meeting Public health challenges for controlling HCV infection WHO informal consultation with VHPB Geneva, May 13-14, 2002. Prof Alessandro Zanetti Institute of Virology – University of Milan. Hepatitis C: a major worldwide public health problem. 170 million chronic carriers.

lanai
Download Presentation

Meeting Public health challenges for controlling HCV infection

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Meeting Public health challenges for controlling HCV infection WHO informal consultation with VHPB Geneva, May 13-14, 2002 Prof Alessandro Zanetti Institute of Virology – University of Milan

  2. Hepatitis C:a major worldwide public health problem • 170 million chronic carriers • In developed countries the incidence has • progressively declined for: • improvment of general standard of living • and hygiene • introduction of general public health mea- • sures (screening for safe blood, use of • disposable syringes and needles, universal • precautions in medical settings, etc)

  3. Strategies for primary prevention of HCV • Identification of carriers and acutely • infected individuals (counselling, • treatment) • Interruption of the viral chain of • transmission

  4. Measures to prevent hepatitis C transmission through: • Transfusion • I. V. drug use and other parenteral exposures • Nosocomial • Sexual • Household contact and daily life • Vertical/perinatal

  5. Blood transfusion safety: prevention strategies • Selection of periodic, volunteer, • unremunerated donors • Evaluation of medical and personal history • Confidential unit exclusion • Implementation of donors screening • Viral inactivation • Proper use of blood, blood components • and derivates

  6. Residual risk of transfusion-transmitted viral infections • Mostly related to the pre-seroconversion window period. • The probability of transmitting HCV through transfusion of screened blood is related to the length of the pre-seroconversion window phase and the incidence of HCV infection among donors. • The magnitude of residual risk may differ within countries depending on the sensitivity of the assays used for screening and on the level of HCV endemicity.

  7. Residual risk of transfusion-associated HCV infection in Italy (Transfusion 2002, in press) Methods Matematical model (incidence/ window-period model) Study populationSite: Lombardy Period: Jan 1996-Dec 2000 n° records examined for periodic, volunteer, unpaid donors: 2, 411, 800 Mean donors per year: 223,500 Donation index: 2.1 Laboratory 3rd generation EIA supplemental assays

  8. Estimated residual risk of transmitting HCV/HIV by transfusion of antibody-screened blood Year Residual risk Estimated donations +ve during the window HCVHIV phase x 106 donations (95%CI) (95%CI) HCVHIV 1996 1: 90,909 1:357,142 11 2.8 1997 1: 100,000 1:370,370 10 2.7 1998 1 : 163,934 1:1,000,000 6.1 1 1999 1 : 158,730 1:400,000 6.3 2.5 2000 1 : 181,818 1:400,000 5.5 2.5 Total 1 : 126,582 1:434,782 7.9 2.3 (100,000-175,438) (333,333-588,235) (5.7-10) (1.7-3)

  9. Estimated residual risk to the blood supply in Europe and in the USA Cases per 106 donations Lombardy 18 15.03 16 14 12 9.7 2 10 7.9 8 6 4.481 4 2.03 2 2.3 1.75 1 2 0.58 3 0 HCV HIV 1Couroucé (1996);2Schreiber (1996);3Allain (1997)

  10. Residual risk of transfusion-transmitted HCV • It is currently very small in developed • countries. • The safety of blood supply remains a major • source of public concern, requiring a continous • effort to reach zero-risk. • NAT can shorten the window period and, • consequently, further reduce the residual risk • of HCV transmission.

  11. Declining time to detection of HCV/HIV markers during the window phase following infection HCV RNA HCV Ag EIA 3.0 EIA 2.0 EIA 1.0 0 13 14 70 80 150 (days) Infection HCV HIV RNA p24 Ag EIA 3.0 0 11 16 22 (days) Infection HIV

  12. Estimated reduction of the residual risk of transfusion-transmitted HCV (7.9 x 106 donations) and HIV (2.3 x 106 donations) by using direct viral detection assays in combination with the existing serologic assays Estimated window Estimated window %Reduction Project yeld (infected Estimated phase period phase reduction unit detected x106 Residual Risk (days) (days) units) x106 donations HCV: NAT 13 57 81.4 6.4 1.5 cAg 14 56 80 6.3 1.6 HIV: NAT 11 11 50 1.15 1.15 p24 16 6 28 0.6 1.7

  13. Measures to reduce risk of transfusion-associated hepatitis C • Solvent/detergent treatment of plasma and • derivates (utilized with success against enveloped • viruses). • Photochemical decontamination using psoralen • and UV light (effective to inactivate a wide range • of viruses). • The possibility to inactivate also agents whose • genomic sequences are unknown (not detectable • by NAT) offers the potential for approaching • of zero risk associated to transfusion.

  14. HCV transmission by i.v. drug use • In many developed countries, drug use is the • major source of HCV infection. • In Europe up to 60-70% of IVDUs living in urban • areas of the major cities, are anti-HCV positives. • The rate of infection depends on the lenght of • the time of drug abuse (25% of infection during • the first year of addiction, 50% after 5 years • and up to 90% for more than 5 years of use).

  15. Prevention of HCV transmission by i.v. drug use (1) • Need of extensive education campaigns aimed: • to prevent initiation of drug use • to reduce harm-behaviours • to avoid sharing of syringes and needles, • water or drug preparation equipments.

  16. Prevention of HCV transmission by i.v. drug use (2) • For IVDUs who cannot or will not stop injecting • drugs: • Easy access to sterile syringes*(syringe exchange • program), accompanied by counselling and health • education. • Safe disposal of used syringes (to reduce the chance • of re-use of blood-contamined syringes and to assure • the community about the risk of discarded syringes • in the neighborhoods). * some countries have legal restrictions on the sale and distribution of sterile syringes

  17. Piercing, tatooing • Education on the potential risk of acquiring blodd-borne viruses through indequates sterilized equipment, including needles. • Tattoing makers must follow infection-control • procedures (i.e. using gloves, cleaning and • disinfecting surfaces, etc).

  18. Nosocomial and occupational exposure • Nosocomial transmission of HCV through unsafe • injections and other medical practices or through • unscreened blood remains a major problem in • developing countries. • In developed countries, HCV spread is mainly • related to non-strict observance of universal • precaution measures (indequate disinfection/ • sterilization, sharing of medication vials and supplies • and contamined equipment).

  19. Modalities of acquiring blood-borne viruses in health-care settings • Nosocomialfrom the environment to the • patient or from patient-to-patient • Occupationalfrom an infected patient to the • HCW • From an HCW to the patient

  20. Nosocomial transmission of HCV • Anedoctical cases as well as outbreaks of HCV • are documented, especially in hemodialysis • and in haematologic settings. • Out patients facilities (i.e. endoscopic services • and dentist’s surgery) also represent high-risk • settings.

  21. Measures to control and prevent nosocomial transmission of HCV • Strict observance of universal precautions. • Education and training of HCWs to the proper use • of standard precautions including vaccination • against HBV. • Hemodialysis setting • Precautions should be even more stringents. • Patients should have assigned specific dialysis stations. • Clean and contamined areas should be separated. • Isolation of HCV infected patients is not • recommended.

  22. Occupational risk of acquiring HCV in health-care settings and measures to prevent it • Risk is low. • Follow-up studies of needlestick from HCV+ • sources indicate a 1-10% seroconversion rate in • recipients (mean risk of 1.8%). • From an Italian study carried out on 3,795 expo- • sures to HCV, the rate of transmision was 0.4% • (0.9% in cases of exposures to hollow needles and • 0.3% for conjunctival exposure)*. • Standard barrier precautions and engineering • controls should be implemented to prevent infection. *Eurosurveillance 1999; 4:33.

  23. Transmission of HCV from HCWs to patients and measures to prevent it • Transmission can occur but is very rare. • To date, six reports of confirmed transmission of • HCV from HCWs to patients have been published, • including a Spanish anesthesiologist addicted to • oppioids who infected nearly 200 patients. • Look back of 2,286 women who had been operated • between January ’93 and March 2000 by an HCV • infected gynecologist, showed that only one • (0.04%) woman acquired infection by the • surgeon (Arch Intern Med 2002; 162: 805).

  24. HCV-Provider-to-Patient Transmission Published Cases Case 1 An HCV-positive surgeon infected a patient during valve replacement surgery. Case 2 A highly viremic cardiothoracic surgeon infected five of his patients intraoperatively between 1988 and 1993. Cases 3 and 4 HCV provider-to-patient transmissions by two gynecologists. Case 5 An HCV-positive anesthesiologist transmitted the virus during a cardiothoracic operation. Case 6 A Spanish anesthesiologist addicted to opioids infected almost 200 of his patients intentionally. Esteban et al., 1996; Duckworth et al., 1999; UK Health Department, 2000; Bosch, 2000; Garfein, 2000

  25. Management of HCV infected HCWs • No need to screen HCWs and no recommendations • (CDC, EASL) exist to restrict professional activities • of infected HCWs who, hovewer, must follow strict • aseptic tecniques and universal precautionary • measures. • According to a Consensus Conference held at the • ISS in Rome*, HCV infected (RNA+) HCWs should • abstain from directly performing invasive • (exposure prone) procedures while no other • limitations in their activities are necessary. • *Digest Liver Dis 2001; 33:795.

  26. It occurs but the virus is inefficiently transmitted • through this route. Sexual transmission of HCV • Sex is a common behaviour and the existence of • a large reservoir of HCV carriers provides multiple • opportunities for exposure to potentially infected • partners. • Adolescents and young adults, individuals with • multiple partners, prostitutes and their clients, • patients with STDs, partners of HCV and HIV co- • infected persons are at the increased risk of • acquiring HCV sexually. • No reliable HCV markers (i.e. genotype or HCV load) • canpredict transmission.

  27. Prevention of sexual transmission of HCV • Counselling and education (especially for adole- • scents). • Individuals in long-term monogamous relationship • should be informed of the low risk of transmission • and encouraged to discuss the risk and the use of • barrier protections with sexual partners. • The use of condom is strongly recommended for • individuals with multiple partners, with STDs • and for IVDUs. • There is no clear evidence that prophylaxis • with Ig canevent sexual transmission of HCV.

  28. Prevention of HCV transmission (Household contacts and “daily life”) • HCV can be percutaneously transmitted within families. • Infected persons should be informed on preventive • measures. • Prevention includes avoiding shared use of razors, • toothbrushers and any item that pierces the skin. • Sharing meals or eating utensiles is not a known • risk factor. • “Daily life” is not a risk factor. • There is no evidence to justify exclusion of anti-HCV + • individuals from partecipation in social, educational • or employment activities.

  29. Hepatitis C and pregnancy • Pregnancy is not contraindicated in women with HCV. • Maternal infection does not appear to affect pregnancy • adversely nor does pregnancy have adverse effects on • the course of the liver disease. • A woman with HCV infection should not be counselled • against becoming pregnant. • The major issue raised by HCV infection during pre- • gnancy is how to decrease the risk of viral transmis- • sion to the newborn. • Available drugs cannot be used in pregancy since they • are teratogenic (Ribavirin) or have adverse effects on • fetal growth (Interferon).

  30. Mother-to-child transmission of HCV (1) • Risk is less than 5% but is higher for babies • born to woman with HIV co-infection. • Transmission is restricted to infants whose • mothers are viremic (RNA+). • Risk of infection increases with increasing • maternal viral load, but a specific cut-off value • which predicts transmission cannot be defined. • Transmission is not related to specific genotypes.

  31. Mother-to-child transmission of HCV (2) • There is no evidence to support that caesarean delive- • ry may reduce risk of HCV transmission compared to • vaginal delivery. • The role of obstetric variables such as type of vaginal • delivery (spontaneous, induced, operative), duration of • rupture membranes and timing of caesarean section • (before, during labour) remains largely unexplored. • The safety of obstetric procedures (use of monitoring • devices and different instruments) during pregnancy • in mothers HCV+ is not well documented. • Caution should be recommended in using any invasive • procedures (i.e. chorionic villous sampling, amniocente- • sis, cord blood sampling) that may expose the fetus or • the neonate to maternal blood.

  32. Mother-to-infant transmission of HCV • HCV can be detectable in colostrum and milk but • breastfeeding appears to be safe and is not • contraindicated. • Factors that might modify the risk of viral trans- • mission by breastfeeding (i.e. duration of lacta- • tion, levels of HCV-RNA in colostrum and milk, • exposure to chapped nipples) require further • studies.

  33. Assisted reproductive techniques • There are insufficient data on the interaction between • HCV infection and ART to make recommendations. • If the woman is infected, the couple should counselled • on the potential risk of mother-to-child transmission. • If the male is infected, there is a potential risk of • transmission to female if semen contains HCV. • Over 1400 intrauterine inseminations attempts with • processed semen of males HCV+ have been perfor- • med without a case of transmission to the uninfected • partner (1). • There is no report of HCV transmission through • heterologous gametes by individuals infected with • HCV, but is recommended to select uninfected donors. • 1.Semprini AE - personal communication

  34. Persons who should be screened for HCV infection • Persons who received transfusion or solid • trasplants prior to donor screening (1991) • Haemophiliacs • HCWs after percutaneous or mucosal exposure • to anti-HCV+ blood • IVDUs • Hemodialyzed patients • Donors of blood, organ or tissue transplantation • Children born to mothers with hepatitis C

  35. HCV screening • Screening should be accompained by pre and • post-counselling. • Screening is not recommended for general po- • pulation as well as for pregnant woman (or limi- • ted to woman undergoing prenatal invasive • procedures?) and HCWs (except those involved in • exposure prone procedures). • Future availability of effective drugs to treat • infections and of a protective vaccine might • change our current strategy for screening.

More Related